These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 34552325

  • 1. Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England.
    Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2591-2604. PubMed ID: 34552325
    [Abstract] [Full Text] [Related]

  • 2. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K.
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [Abstract] [Full Text] [Related]

  • 3. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR, Zhou S, Shaikh A, Willey VJ.
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [Abstract] [Full Text] [Related]

  • 4. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.
    Int J Chron Obstruct Pulmon Dis; 2018 May; 13():781-792. PubMed ID: 29551894
    [Abstract] [Full Text] [Related]

  • 5. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ.
    Int J Chron Obstruct Pulmon Dis; 2016 May; 11():2851-2858. PubMed ID: 27920512
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
    Lee CH, Kim MS, Yeo SH, Rhee CK, Park HW, Yang BR, Lee J, Cho EY, Xu X, Navarro Rojas AA, Shantakumar S, Milea D, Choi NK.
    Respir Res; 2022 Sep 05; 23(1):231. PubMed ID: 36064539
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019 Sep 05; 14():2121-2129. PubMed ID: 31571848
    [Abstract] [Full Text] [Related]

  • 10. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE, Kaila S, Bayer V, Shaikh A, Shinde MU, Willey VJ, Napier MB, Singer JR.
    J Manag Care Spec Pharm; 2019 Feb 05; 25(2):205-217. PubMed ID: 30698096
    [Abstract] [Full Text] [Related]

  • 11. Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.
    Singh MP.
    Int J Chron Obstruct Pulmon Dis; 2013 Feb 05; 8():613-9. PubMed ID: 24353411
    [Abstract] [Full Text] [Related]

  • 12. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B, Small M, Holmgren U.
    Int J Chron Obstruct Pulmon Dis; 2017 Feb 05; 12():1527-1537. PubMed ID: 28579771
    [Abstract] [Full Text] [Related]

  • 13. COPD exacerbations by disease severity in England.
    Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM.
    Int J Chron Obstruct Pulmon Dis; 2016 Feb 05; 11():697-709. PubMed ID: 27099486
    [Abstract] [Full Text] [Related]

  • 14. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
    Singer D, Bengtson LGS, Elliott C, Buikema AR, Franchino-Elder J.
    Int J Chron Obstruct Pulmon Dis; 2020 Feb 05; 15():3239-3250. PubMed ID: 33324047
    [Abstract] [Full Text] [Related]

  • 15. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
    Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, Feigler N, Patel S, Pollack M.
    Int J Chron Obstruct Pulmon Dis; 2022 Feb 05; 17():329-342. PubMed ID: 35177901
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 05; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G, Nava S, Ventrella F, Bussoli G, Catapano GA, Pennisi A, Dadduzio F, Schino P, Pela R, Bartezaghi M, Morini P, Porpiglia PA, Muscianisi E, Mistral study group.
    Pulm Pharmacol Ther; 2018 Dec 05; 53():68-77. PubMed ID: 30193866
    [Abstract] [Full Text] [Related]

  • 19. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
    Ivanov Y, Nikolaev I, Nemeth I.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 05; 13():653-663. PubMed ID: 29503539
    [Abstract] [Full Text] [Related]

  • 20. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V, Corhay JL, Germonpré P, Janssens W, Joos GF, Liistro G, Vincken W, Gurdain S, Vanvlasselaer E, Lehouck A.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 05; 12():793-801. PubMed ID: 28293106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.